Once considered a NASDAQ darling just three years ago, mishap after mishap led to a steep decline in stock value for genetic-testing company, 23andMe. Now its CEO is inching closer and closer to taking the company private. After a 6 billion dollar valuation in 2021, what led to this dramatic decline? 23andMe Becomes A Penny […]
The post After Declining Stock, 23andMe Goes Private appeared first on GCTV.
